GYRE Gyre Therapeutics, Inc.
Mergers ·
Gyre closed its merger with Cullgen on May 4, 2026. Cullgen holders get Gyre common and Series B preferred stock, and Cullgen's former CEO Ying Luo becomes Gyre's CEO.
Gyre Therapeutics agreed to buy privately held Cullgen in an all-stock deal valued at about $300 million, issuing common stock and Series B convertible preferred. Until stockholders approve the conversion, Gyre may not issue more than 19.99% of its stock, and Cullgen's lead drug has completed only a Phase 1 trial.
Jefferies LLC is the sales agent for up to $50,000,000 of common stock. Its commission is up to 3.0% of gross proceeds, and a significant part of the business runs through a Chinese subsidiary.
Gyre Therapeutics, Inc. is a commercial-stage biopharmaceutical company focused on small-molecule therapies for organ fibrosis and inflammatory diseases. It operates in the PRC through its majority indirectly owned subsidiary, Beijing Continent Pharmaceuticals Co., Ltd. (d/b/a Gyre Pharmaceuticals Co., Ltd.), and has U.S. operations headquartered in San Diego, California. Its commercial portfolio in the PRC is built on ETUARY (pirfenidone) for idiopathic pulmonary fibrosis, which generated annual sales of $106.1 million in 2025. The portfolio also includes Etorel (nintedanib), approved as a standard-of-care therapy for IPF and two other fibrotic lung diseases, and Contiva (avatrombopag) for thrombocytopenia associated with chronic liver disease. Its lead development candidate is Hydronidone, a derivative of pirfenidone, which the company is developing for CHB-associated liver fibrosis in the PRC and MASH-associated liver fibrosis in the United States. On March 2, 2026, the company agreed to a merger with Cullgen Inc., under which Cullgen would become a wholly owned subsidiary of Gyre, subject to Cullgen stockholder approval and an HSR Act filing.
| Product or program | What it is | Stage |
|---|---|---|
| ETUARY (pirfenidone) | Anti-fibrotic therapy for idiopathic pulmonary fibrosis in the PRC | approved in the PRC |
| Etorel (nintedanib) | Antifibrotic therapy for IPF and related fibrosing lung diseases in the PRC | approved in the PRC |
| Contiva (avatrombopag) | Oral thrombopoietin receptor agonist for thrombocytopenia with chronic liver disease | approved in the PRC |
| Hydronidone (F351) | Pirfenidone derivative for CHB-associated and MASH-associated liver fibrosis |
| Line | FY2025 | FY2024 |
|---|---|---|
| Research and development | $13.7 million | $12.0 million |
| Net income (loss) | $9.9 million | $17.9 million |
| Cash from operations | $1.0 million | -$3.6 million |
| Cash and equivalents | $49.2 million | $11.8 million |
| Short-term investments | $15.4 million | $14.9 million |
Our latest story on this, dated Nov 27, 2024: "Gyre Therapeutics sets up $50,000,000 at-the-market stock program with Jefferies". The story links the filing or release it is based on. Read the story.
Our latest story on this, dated Mar 2, 2026: "Gyre Therapeutics agrees to acquire Cullgen in all-stock deal valued at about $300 million". The story links the filing or release it is based on. Read the story.
Our latest story on this, dated May 4, 2026: "Gyre Therapeutics completes all-stock acquisition of Cullgen valued at about $300 million". The story links the filing or release it is based on. Read the story.
Gyre Therapeutics, Inc. trades under the ticker GYRE on NASDAQ.
Gyre Therapeutics, Inc. is listed on NASDAQ. Our directory also records these other listings: GETTEX:L9S.
The SEC Central Index Key (CIK) for Gyre Therapeutics, Inc. is 1124105. Its filings are on SEC EDGAR.
111,509,849 shares as of 2026-08-01, per the cover page of its 10-Q filed 2026-08-07.
Our directory records Gyre Therapeutics, Inc. under United States.
Our directory classifies Gyre Therapeutics, Inc. as: Pharmaceuticals: Major. This is a directory classification, not a description of the pipeline.
The ISIN recorded for Gyre Therapeutics, Inc. is US4037831033.
aibio.space lists Gyre Therapeutics, Inc. among 2,820 public biotech companies and publishes its news here as stories appear.
SEC records list its state or country of incorporation as DE.
Gyre Therapeutics, Inc. is a commercial-stage biopharmaceutical company focused on small-molecule therapies for organ fibrosis and inflammatory diseases. It operates in the PRC through its majority indirectly owned subsidiary, Beijing Continent Pharmaceuticals Co., Ltd. (d/b/a Gyre Pharmaceuticals Co., Ltd.), and has U.S. operations headquartered in San Diego, California.
ETUARY (pirfenidone): Anti-fibrotic therapy for idiopathic pulmonary fibrosis in the PRC Stage: approved in the PRC.
Etorel (nintedanib): Antifibrotic therapy for IPF and related fibrosing lung diseases in the PRC Stage: approved in the PRC.
Reported completing an acquisition or a sale of assets. SEC Form 8-K (Items 2.01,3.02,3.03,5.02,5.03,7.01,9.01). Source
Reported a merger or acquisition agreement. SEC Form 8-K (Items 1.01,3.02,5.02,5.03,7.01,9.01). Source
Filed a final prospectus for a securities offering. SEC Form 424B5. Source
Reported a financing. SEC Form 424B5. Source
Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction
aibio